ACAD - アカディア・ファ―マシュ―ティカルズ (ACADIA Pharmaceuticals Inc.) アカディア・ファ―マシュ―ティカルズ

 ACADのチャート


 ACADの企業情報

symbol ACAD
会社名 Acadia Pharmaceuticals Inc (アカディア・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アカディア・ファーマシューティカルズ(ACADIA Pharmaceuticals Inc.)は神経と関連の中枢神経系疾患における満たされていない医療ニーズに応じた小分子薬事業を中心とするバイオ医薬品会社。同社は第III相開発段階におけるパーキンソン病精神病のためのファーストインクラスの治療薬である「pimavanserin」を含む4種類の製品候補を有する。同社は「pimavanserin」に対してグローバルな販売権を持つ。更に、同社はAllergan Inc.と連携して開発する慢性痛治療用の第II相試験にある薬品候補及び緑内障治療用の第I相試験にある薬品候補を有し、並びにMeiji Seika Kaisha Ltdと連携して開発する統合失調症治療用第I相開発段階における薬品候補も有する。同社の臨床段階における薬品候補は「Pimavanserin」、「Alpha Adrenergic Agonists」、「Muscarinic Agonist」と「AM-831」を含む。  アカディア・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。神経および関連中枢神経系疾患に対する治療薬に焦点を当て、主に、パ―キンソン病、精神分裂病、神経痛、アルツハイマ―病などの治療に関係する治療薬候補を開発する。本社は、カリフォルニア州サンディエゴ。   ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
本社所在地 3611 Valley Centre Drive Suite 300 San Diego CA 92130 USA
代表者氏名 Stephen R. Biggar スティーブン・R・ビガール
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-558-2871
設立年月日 34151
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 425人
url www.acadia-pharm.com
nasdaq_url https://www.nasdaq.com/symbol/acad
adr_tso
EBITDA EBITDA(百万ドル) -251.19800
終値(lastsale) 21.11
時価総額(marketcap) 2638891922.53
時価総額 時価総額(百万ドル) 2645.142
売上高 売上高(百万ドル) 185.07100
企業価値(EV) 企業価値(EV)(百万ドル) 2388.287
当期純利益 当期純利益(百万ドル) -182.79200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ACADIA Pharmaceuticals Inc. revenues increased from $45.8M to $105.9M. Net loss decreased 24% to $117.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income net increase of 25% to $2.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.27 to -$0.94.

 ACADのテクニカル分析


 ACADのニュース

   ACADIA Pharmaceuticals : 2Q20 Earnings Presentation | MarketScreener  2020/08/05 20:22:03 MarketScreener
Second Quarter 2020 Earnings Call A U G U S T 5 , 2 0 2 0 2Q 2020 Earnings Call Agenda … | August 5, 2020
   ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results  2020/08/05 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020. “In the first half of 2020 we drove robust growth of NUPLAZID®. With the FDA filing of our sNDA for dementia-related psychosis we are one step closer to potentially delivering
   People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights  2020/07/29 13:00:00 Business Wire
WASHINGTON & ATLANTA & SAN DIEGO--(BUSINESS WIRE)--UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to better understand the patient-centered experience of symptoms and unmet treatment needs. Both patients and caregivers responded to the survey. These data were presented today in two posters d
   ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020  2020/07/22 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Wednesday, August 5, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and
   ACADIA Pharmaceuticals : Corporate Update Presentation | MarketScreener  2020/07/20 20:26:10 MarketScreener
ACADIA Corporate Update J u l y 2 0 , 2 0 2 0 Agenda … | July 20, 2020
   2020 Depression Pipeline Landscape Insights: H1  2020/04/27 16:45:00 Benzinga Feeds
DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide provides an overview of the Depression (Central Nervous System) pipeline landscape. It provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. It also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively.
   ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020  2020/04/15 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-
   Goldman likes GW Pharma in premarket analyst action  2020/03/06 12:22:23 Seeking Alpha
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup. Alector (NASDAQ:ALEC) initiated with Buy rat
   ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome  2020/03/03 22:50:00 Business Wire
SAN DIEGO & MELBOURNE, Australia--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA r
   ACADIA Pharma EPS beats by $0.03, beats on revenue  2020/02/26 21:13:40 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD): Q4 GAAP EPS of -$0.34 beats by $0.03. Revenue of $98.33M (+65.0% Y/Y) beats by $1.64M. Press Release
   2020 Depression Pipeline Landscape Insights: H1  2020/04/27 16:45:00 Benzinga Feeds
DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide provides an overview of the Depression (Central Nervous System) pipeline landscape. It provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. It also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively.
   ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020  2020/04/15 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-
   Goldman likes GW Pharma in premarket analyst action  2020/03/06 12:22:23 Seeking Alpha
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup. Alector (NASDAQ:ALEC) initiated with Buy rat
   ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome  2020/03/03 22:50:00 Business Wire
SAN DIEGO & MELBOURNE, Australia--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA r
   ACADIA Pharma EPS beats by $0.03, beats on revenue  2020/02/26 21:13:40 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD): Q4 GAAP EPS of -$0.34 beats by $0.03. Revenue of $98.33M (+65.0% Y/Y) beats by $1.64M. Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アカディア・ファ―マシュ―ティカルズ ACAD ACADIA Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)